AKT1 and cancer: Combination treatment with VVD-699 and sotorasib suppressed both PI3K/AKT and ERK signaling at 2 and 24 hours, indicating that this combination can be used to more durably suppress the PI3K/AKT and MAPK pathways in KRASGly12Cys driven cancers (Fig. 5B, Fig. S5B).